Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
4 reports, 1 independent
Updated Sep 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Beam Therapeutics
American healthcare company
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
-
Bank of America
American multinational banking and financial services corporation
Related events
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup boosted its price target and gave a buy rating for Wholesale Club, with MarketBeat providing consensus data.
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Amphenol received multiple analyst upgrades and target price increases from firms including Citigroup, Bank of America, and Jefferies Financial Group on July 9, 2026.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.